Novartis Reports Histology Data of CFZ533 (iscalimab) in Kidney Transplantation for Extended Survival of Transplanted Organs

Novartis Reports Histology Data of CFZ533 (iscalimab) in Kidney Transplantation for Extended Survival of Transplanted Organs

Shots:

  • The study involves assessing of calcineurin-free treatment with iscalimab vs tacrolimus to test the durability of transplanted kidney grafts and improve long-term outcomes for kidney transplant patients
  • The study resulted in 60% normal kidney histology@1 year for iscalimab-treated transplant patients with lower chronic allograft damage index (CADI) scores, Presented at American Transplant Congress (ATC) 2019
  • Iscalimab is a mAb that prevents CD40 pathway signaling, further activates CD40+ cell types and is currently evaluated in P-IIb trial (Cirrus I, NCT03663335)

Click here to read full press release/ article | Ref: Novartis | Image: Xtra Shot